Literature DB >> 23175560

Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.

Shamez N Ladhani1, Nick J Andrews, Pauline Waight, Ray Borrow, Mary P E Slack, Elizabeth Miller.   

Abstract

BACKGROUND: Streptococcus pneumoniae is an uncommon but well-recognized cause of invasive bacterial disease in young infants. This study aimed to determine the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in infants aged <90 days in England and Wales and describe their clinical characteristics following PCV7 introduction.
METHODS: Trends in IPD among infants aged <90 days during 1998-1999 through 2009-2010 were analyzed using enhanced national surveillance data. Following PCV7 introduction, clinical information was also obtained for IPD cases in the birth cohorts eligible for vaccination.
RESULTS: Prior to PCV7 introduction, IPD incidence in infants aged <90 days was 13.0 (95% confidence interval [CI], 12.0-14.0) per 100 000 live births and PCV7 serotypes accounted for 44% (154/349) of serotyped isolates. PCV7 introduction resulted in 83% (95% CI, 66%-91%, P < .001) reduction in PCV7 IPD and a declining trend in overall IPD by 2009-2010. Of the 256 cases diagnosed after PCV7 introduction, 23% (n = 60) had been born before 37 weeks' gestation. A third of cases (84/256, 33%) developed IPD in the first 48 hours of life, where 42% (35/84) were premature. Meningitis was diagnosed in 94 infants (37%) and its prevalence increased with age. Case fatality was 7% (18/256) and was higher for meningitis than nonmeningitis cases (adjusted odds ratio, 3.8 [95% CI, 1.2-12.0], P = .024).
CONCLUSIONS: Young infants have benefited from PCV7 through indirect (herd) protection. Given that a third of cases occurred within 48 hours of birth, further studies should focus on risk factors for IPD in pregnancy and strategies to prevent mother-to-child transmission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175560     DOI: 10.1093/cid/cis934

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes.

Authors:  Hans-Christian Slotved
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

2.  Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7.

Authors:  Liset Olarte; Krow Ampofo; Chris Stockmann; Edward O Mason; Judy A Daly; Andrew T Pavia; Carrie L Byington
Journal:  Pediatrics       Date:  2013-06-03       Impact factor: 7.124

3.  Molecular characterization and antimicrobial susceptibility of Streptococcus pneumoniae isolated from children hospitalized with respiratory infections in Suzhou, China.

Authors:  Qian Geng; Tao Zhang; Yunfang Ding; Yunzhen Tao; Yuzun Lin; Yunzhong Wang; Steven Black; Genming Zhao
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

4.  Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data.

Authors:  Daniel M Weinberger; Keith P Klugman; Claudia A Steiner; Lone Simonsen; Cécile Viboud
Journal:  PLoS Med       Date:  2015-01-06       Impact factor: 11.069

5.  Invasive pneumococcal isolates from Danish infants (0 - 90 Days) during the years 1943 to 2013.

Authors:  Hans-Christian Slotved; Tine Dalby; Steen Hoffmann
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

6.  Changing Incidence of Invasive Pneumococcal Disease in Infants Less Than 90 Days of Age Before and After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Blantyre, Malawi: A 14-Year Hospital Based Surveillance Study.

Authors:  Marianne Koenraads; Todd D Swarthout; Naor Bar-Zeev; Comfort Brown; Jacquline Msefula; Brigitte Denis; Queen Dube; Stephen B Gordon; Robert S Heyderman; Melissa J Gladstone; Neil French
Journal:  Pediatr Infect Dis J       Date:  2022-06-13       Impact factor: 3.806

7.  Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies.

Authors:  Naor Bar-Zeev; Todd D Swarthout; Dean B Everett; Maaike Alaerts; Jacquline Msefula; Comfort Brown; Sithembile Bilima; Jane Mallewa; Carina King; Anne von Gottberg; Jennifer R Verani; Cynthia G Whitney; Charles Mwansambo; Stephen B Gordon; Nigel A Cunliffe; Neil French; Robert S Heyderman
Journal:  Lancet Glob Health       Date:  2021-07       Impact factor: 38.927

Review 8.  The changing epidemiology of childhood pneumococcal disease in Korea.

Authors:  Young June Choe; Eun Hwa Choi; Hoan Jong Lee
Journal:  Infect Chemother       Date:  2013-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.